▶ Full Post Text
VANCOUVER, BC, January 15th,2026/ - TheNewswire - BioVaxys Technology Corp. (CSE:BIOV) (FRA: 5LB) (OTCQB: [BVAXF](https://www.prnewswire.com/news-releases/biovaxys-to-participate-in-the-us-government-biomedical-advanced-research-and-development-authority-barda-rapid-response-partnership-vehicle-rrpv-vaccine-development-consortium-302296410.html#financial-modal)) ("BioVaxys" or the"Company") is pleased to provide an update on 1Q2026initiatives, including collaborations and non-dilutive fundingprograms.
The Company is pleased to announce that it is participating in aRequest for Information (RFI) solicitation issued by the USGovernment's Biomedical Advanced Research and DevelopmentAuthority (BARDA) for transformative ‘New Vaccine Platforms’ thatcan enable efficient development timelines in response to emerginginfectious disease threats. BARDAs mission is to accelerate medicalcountermeasure product and technology development to address evolvingneeds including pandemic influenza, emerging infectious diseases, andother biological threats. The RFI issued by BARDA is the precursorto a subsequent Request for Proposal (RFP), which is issued followingBARDA’s assessment of novel vaccine platforms submitted during theRFI process. Having a role at the start during the RFI processensures that the capabilities of BioVaxys’ DPX platform areconsidered when designing the development program needs for the RFP.
Through high-level introductions by the BioVaxys Board, the Companyrecently initiated discussions for a vaccine development collaborationwith a United Nations-chartered international organization dedicatedto discovery, development, and delivery of safe, effective, andaffordable vaccines for global health initiatives. With a researchbudget of nearly US$120M, the organization is working to address unmetneeds for Shigella, Hep B, Influenza, RSV, Rotavirus, ZIKA, HPV, andother globally critical pathogens. Kovan adds “Attributes of ourDPX platform that are attractive to their vaccine development effortsinclude features such as duration of immune-activity, single-dosenon-systemic delivery, shelf stability, and micro-dosing capabilities. DPX is uniquely positioned as a solution for antigen packaging anddelivery for vaccines urgently needed in both the developed anddeveloping world.” The Company anticipates further developmentsover the next several weeks as discussions continue.
Last month the Company shared that it was working with an additionalprospective partner in the animal health field to advance a researchcollaboration for a proof-of-product program to evaluate a DPX™formulation of a proprietary mRNA sequence for diseases requiringlong-duration protection, such as rabies. “Since early January, weare jointly reviewing the study design and timelines for a DPX-mRNArabies vaccine program, in anticipation that the protocol is to befinalized and shortly announced. The Company says it’s alreadyestablished that DPX provides enhanced in vitro and in vivo stabilityof packaged mRNA, attracts a therapeutically unique subset of AntigenPresenting Cells (APCs) to the injection site for targeted uptake ofmRNA by the immune system, and that immunization with DPX containingmRNA induces specific immune responses towards encoded antigen. Gaining additional preclinical data with a DPX-mRNA rabiesformulation not only expands our pipeline, but we expect it to opennew partnering discussions in the human mRNA vaccine space,” notedKenneth Kovan, BioVaxys President and Chief Operating Officer.
BioVaxys recently announced positive results from a phase 1 clinicalstudy of MVP-S with neoadjuvant hormone therapy in HR+ / HER2- stageII-III breast cancer, and positive Phase 1 study results with theirDPX-SurMAGE and maveropepimut-S (MVP-S) cancer vaccines in patientswith multiple previous recurrences of high grade non-muscle invasivebladder cancer (NMIBC), where treatment with either MVP-S orDPX-SurMAGE was shown to be well tolerated with both products inducingsignificant systemic antigen-specific T cell responses. After anaverage two years of follow-up post-treatment, many of thesehigh-grade NIMBC patients were free of recurrence. This simple andwell tolerated approach may be a valuable alternative to the manyintravesical and systemic treatments currently being developed.
BioVaxys is reviewing data with Principal Investigators from anadditional phase 1B/2 clinical study with MVP-S in a differentformulation combination and anticipates results in the upcoming weeks.
The BioVaxys DPX platform is a major innovation in vaccine developmentthat offers a solution to limitations faced by vaccines using otherantigen delivery methods. The DPX platform presents antigens to theimmune system using a novel non-systemic mechanism of action that doesnot release active ingredients at the site of the injection but ratherforces an active uptake of immune cells and delivery into thelymphatic nodes. The programming of immune cells happens in vivo andoffers a more efficient approach that mimics the natural function ofthe immune system. This "no release" mechanism allows for anactive uptake of antigens into immune cells and lymph nodes for asustained activation of the immune system in which the T cell flow issustained over a longer duration than traditional vaccines on themarket.
About BioVaxys TechnologyCorp.
BioVaxys Technology Corp. ([www.biovaxys.com](https://api.newsfilecorp.com/redirect/bg5vbSJpAZ)), abiopharmaceutical company registered in British Columbia, Canada, is aclinical-stage biopharmaceutical company dedicated to improvingpatient lives with novel immunotherapies based on the DPX™immune-educating technology platform and it's HapTenix© tumorcell construct platform, for treating cancers, infectious disease,antigen desensitization for food allergy, and other immunologicaldiseases. Through a differentiated mechanism of action, the DPX™platform delivers instruction to the immune system to generate aspecific, robust, and persistent immune response. The Company'sclinical stage pipeline includes maveropepimut-S (MVP-S), based on theDPX™ platform, in phase IIB clinical development for advancedRelapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinumresistant Ovarian Cancer. MVP-S delivers antigenic peptides from theSurvivin family, a set of well-recognized cancer antigens commonlyoverexpressed in advanced cancers and also delivers an innate immuneactivator and a universal CD4+ T cell helper peptide. MVP-S has been well tolerated andhas demonstrated defined clinical benefit in multiple cancerindications as well as the activation of a targeted and sustained,Survivin-specific anti-tumor immune response. BioVaxys is alsodeveloping DPX™+SurMAGE, a dual-targeted immunotherapy combiningantigenic peptides for both the Survivin and MAGE-A9 cancer proteinsto elicit immune responses to these two distinct cancer antigenssimultaneously, DPX™-RSV for Respiratory Syncytial Virus, DPX+rPAfor peanut allergy prophylaxis, and BVX-0918, a personalizedimmunotherapeutic vaccine using its proprietary HapTenix©'neoantigen' tumor cell construct platform for refractivelate-stage ovarian cancer.
BioVaxys common shares are listed on the CSE under the stock symbol"BIOV" and trade on the Frankfurt Bourse (FSE: 5LB0) and inthe U.S. on the OTC Markets (OTCQB: BVAXF). For more information,visit [www.biovaxys.com](https://api.newsfilecorp.com/redirect/3KXyxtrZWp) andconnect with us on X and LinkedIn.
Link to News & Disclaimer: [https://marketwirenews.com/news-releases/biovaxys-1q2026-r-d-and-collaborative-activity-6621912357595577.html](https://marketwirenews.com/news-releases/biovaxys-1q2026-r-d-and-collaborative-activity-6621912357595577.html)